Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published Online First: 9 September 2008. doi:10.1136/ard.2008.093013
Annals of the Rheumatic Diseases 2009;68:238-241
Copyright © 2009 BMJ Publishing Group Ltd & European League Against Rheumatism.

CLINICAL AND EPIDEMIOLOGICAL RESEARCH

Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort

R Kaiser, C M Cleveland, L A Criswell

Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, University of California, San Francisco, California, USA

Lindsey A Criswell, UCSF Division of Rheumatology, 374 Parnassus, 1st Floor, Box 0500, San Francisco, CA 94143, USA; Lindsey.Criswell{at}ucsf.edu

Objectives: Few studies have examined thrombosis in systemic lupus erythematosus (SLE), none have included Asian-Americans, and most have had small sample sizes. We analysed risk factors for thrombosis in a large, multi-ethnic SLE cohort.

Methods: We studied 1930 SLE subjects, including Caucasians, African-Americans, Asian-Americans and Hispanics. Data were derived from questionnaires and medical records. Documented history of thrombosis was the primary outcome. Explanatory variables included age at SLE diagnosis, gender, ethnicity, disease duration, smoking, antiphospholipid antibody (aPL) status, nephritis and specific medications.

Results: Smoking (OR 1.26, p = 0.011), longer disease duration (OR 1.26 per 5 years p = 0.027x10–7), nephritis (OR 1.35, p = 0.036), aPL positivity (OR 3.22, p<10–9) and immunomodulating medication use (OR 1.40, p = 0.011) were statistically significant risk factors for thrombosis. Younger age at SLE onset was protective (OR 0.52 for age <=20, p = 0.001). After adjusting for disease severity and incorporating propensity scores, hydroxychloroquine use remained significantly protective for thrombosis (OR 0.62, p = 4.91x10–4).

Conclusions: This study confirms that older age at onset, longer disease duration, smoking, aPL positivity, history of nephritis and immunomodulating medication use are risk factors for thrombosis in SLE. These data are the first to confirm in a large and ethnically diverse SLE cohort that hydroxychloroquine use is protective for thrombosis.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest Rheumatology Jobs

Rheumatology Jobs